|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kimura T and Egawa S: Epidemiology of
prostate cancer in Asian countries. Int J Urol. 25:524–531. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hamdy FC, Donovan JL, Lane JA, Mason M,
Metcalfe C, Holding P, Davis M, Peters TJ, Turner EL, Martin RM, et
al: 10-Year Outcomes after monitoring, surgery, or radiotherapy for
localized prostate cancer. N Engl J Med. 375:1415–1424. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lane JA, Donovan JL, Davis M, Walsh E,
Dedman D, Down L, Turner EL, Mason MD, Metcalfe C, Peters TJ, et
al: Active monitoring, radical prostatectomy, or radiotherapy for
localised prostate cancer: Study design and diagnostic and baseline
results of the ProtecT randomised phase 3 trial. Lancet Oncol.
15:1109–1118. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wallis CJD, Saskin R, Choo R, Herschorn S,
Kodama RT, Satkunasivam R, Shah PS, Danjoux C and Nam RK: Surgery
Versus radiotherapy for clinically-localized prostate cancer: A
systematic review and meta-analysis. Eur Urol. 70:21–30. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Abdollah F, Schmitges J, Sun M, Jeldres C,
Tian Z, Briganti A, Shariat SF, Perrotte P, Montorsi F and
Karakiewicz PI: Comparison of mortality outcomes after radical
prostatectomy versus radiotherapy in patients with localized
prostate cancer: A population-based analysis. Int J Urol.
19:836–844. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sooriakumaran P, Nyberg T, Akre O,
Haendler L, Heus I, Olsson M, Carlsson S, Roobol MJ, Steineck G and
Wiklund P: Comparative effectiveness of radical prostatectomy and
radiotherapy in prostate cancer: Observational study of mortality
outcomes. BMJ. 348:g15022014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Abdollah F, Sun M, Thuret R, Jeldres C,
Tian Z, Briganti A, Shariat SF, Perrotte P, Rigatti P, Montorsi F
and Karakiewicz P: A competing-risks analysis of survival after
alternative treatment modalities for prostate cancer patients:
1988–2006. Eur Urol. 59:88–95. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Merino T, San Francisco IF, Rojas PA,
Bettoli P, Zúñiga A and Besa P: Intensity-modulated radiotherapy
versus radical prostatectomy in patients with localized prostate
cancer: Long-term follow-up. BMC Cancer. 13:5302013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sun M, Sammon JD, Becker A, Roghmann F,
Tian Z, Kim SP, Larouche A, Abdollah F, Hu JC, Karakiewicz PI and
Trinh QD: Radical prostatectomy vs radiotherapy vs observation
among older patients with clinically localized prostate cancer: A
comparative effectiveness evaluation. BJU Int. 113:200–208. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bluethmann SM, Mariotto AB and Rowland JH:
Anticipating the ‘silver tsunami’: Prevalence trajectories and
comorbidity burden among older cancer survivors in the United
States. Cancer Epidemiol Biomarkers Prev. 25:1029–1036. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Muramatsu N and Akiyama H: Japan:
Super-aging society preparing for the future. Gerontologist.
51:425–432. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fukagai T, Namiki TS, Carlile RG, Yoshida
H and Namiki M: Comparison of the clinical outcome after hormonal
therapy for prostate cancer between Japanese and Caucasian men. BJU
Int. 97:1190–1193. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Namiki M, Ueno S, Kitagawa Y, Fukagai T
and Akaza H: Effectiveness and adverse effects of hormonal therapy
for prostate cancer: Japanese experience and perspective. Asian J
Androl. 14:451–457. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mohler JL, Armstrong AJ, Bahnson RR,
D'Amico AV, Davis BJ, Eastham JA, Enke CA, Farrington TA, Higano
CS, Horwitz EM, et al: Prostate Cancer, Version 1.2016. J Natl
Compr Canc Netw. 14:19–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kanda Y: Investigation of the freely
available easy-to-use software ‘EZR’ for medical statistics. Bone
Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Robinson D, Garmo H, Lissbrant IF, Widmark
A, Pettersson A, Gunnlaugsson A, Adolfsson J, Bratt O, Nilsson P
and Stattin P: Prostate cancer death after radiotherapy or radical
prostatectomy: A nationwide population-based observational study.
Eur Urol. 73:502–511. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Viani GA, Viana BS, Martin JE, Rossi BT,
Zuliani G and Stefano EJ: Intensity-modulated radiotherapy reduces
toxicity with similar biochemical control compared with
3-dimensional conformal radiotherapy for prostate cancer: A
randomized clinical trial. Cancer. 122:2004–2011. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yu T, Zhang Q, Zheng T, Shi H, Liu Y, Feng
S, Hao M, Ye L, Wu X and Yang C: The effectiveness of intensity
modulated radiation therapy versus three-dimensional radiation
therapy in prostate cancer: A meta-analysis of the literatures.
PLoS One. 11:e01544992016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shimizuguchi T, Nihei K, Okano T,
Machitori Y, Ito K and Karasawa K: A comparison of clinical
outcomes between three-dimensional conformal radiotherapy and
intensity-modulated radiotherapy for prostate cancer. Int J Clin
Oncol. 22:373–379. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Löser A, Beyer B, Carl CO, Löser B,
Nagaraj Y, Frenzel T, Petersen C, Krüll A, Graefen M and Schwarz R:
Toxicity and risk factors after combined high-dose-rate
brachytherapy and external beam radiation therapy in men ≥75 years
with localized prostate cancer. Strahlenther Onkol. 195:374–382.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fang FM, Wang YM, Wang CJ, Huang HY and
Chiang PH: Comparison of the outcome and morbidity for localized or
locally advanced prostate cancer treated by high-dose-rate
brachytherapy plus external beam radiotherapy (EBRT) versus EBRT
alone. Jpn J Clin Oncol. 38:474–479. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
D'Amico AV, Manola J, Loffredo M, Renshaw
AA, DellaCroce A and Kantoff PW: 6-month androgen suppression plus
radiation therapy vs radiation therapy alone for patients with
clinically localized prostate cancer: A randomized controlled
trial. JAMA. 292:821–827. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hanks GE, Pajak TF, Porter A, Grignon D,
Brereton H, Venkatesan V, Horwitz EM, Lawton C, Rosenthal SA,
Sandler HM, et al: Phase III trial of long-term adjuvant androgen
deprivation after neoadjuvant hormonal cytoreduction and
radiotherapy in locally advanced carcinoma of the prostate: The
radiation therapy oncology group protocol 92-02. J Clin Oncol.
21:3972–3978. 2003. View Article : Google Scholar : PubMed/NCBI
|
